Study of Tarceva and Targretin in Stage I-II Lung Cancer

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dartmouth-Hitchcock Medical Center
• Collaborators: Genentech, Inc.; Ligand Pharmaceuticals
• Treatments: Bexarotene; Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Resectable stage I or II non-small-cell lung cancer

• Prior tissue biopsy (not cytology) available for research analysis

• Adequate hepatic and renal function

Exclusion Criteria:

• Prior chemotherapy or radiotherapy